Asset
C16G2
Armata Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03196219 | phase2 | completed | 2017-07-07 | 2017-11-22 | Armata Pharmaceuticals, Inc. | A Phase 2 Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip in Adolescent and Adult Subjects |
| NCT02594254 | phase2 | completed | 2015-11-01 | 2016-06-01 | Armata Pharmaceuticals, Inc. | Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects |
| NCT02254993 | phase2 | completed | 2014-10-01 | 2015-06-01 | Armata Pharmaceuticals, Inc. | Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel Doses |
| NCT02044081 | phase2 | completed | 2014-02-01 | 2014-07-01 | Armata Pharmaceuticals, Inc. | Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth Rinse Doses to Healthy Adults |
| NCT02509845 | phase2 | completed | 2015-07-01 | 2016-02-01 | Armata Pharmaceuticals, Inc. | Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental Subjects |
FDA applications (0)
This company has no applications containing this asset.